Summary: Concerns about long-term methotrexate (MTX) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic MTX administration in children with acute lymphoblastic leukemia. In this study, neurocognitive outcomes and neuroradiologic evidence of leukoencephalopathy were compared in children treated with intense central nervous system (CNS)-directed therapy (P9605) versus those receiving fewer CNS-directed treatment days during intensive consolidation (P9201). A total of 66 children from 16 Pediatric Oncology Group institutions with "standard-risk" acute lymphoblastic leukemia, 1.00 to 9.99 years at diagnosis, without evidence of CNS leukemia at diagnosis were enrolled on ACCL0131: 28 from P9201 and 38 from P9605. Magnetic resonance imaging scans and standard neuropsychological tests were performed Z2.6 years after the end of treatment. Significantly more P9605 patients developed leukoencephalopathy compared with P9201 patients (68%, 95% confidence interval 49%-83% vs. 22%, 95% confidence interval 5%-44%; P = 0.001) identified as late as 7.7 years after the end of treatment. Overall, 40% of patients scored <85 on either Verbal or Performance IQ. Children on both studies had significant attention problems, but P9605 children scored below average on more neurocognitive measures than those treated on P9201 (82%, 14/17 measures vs. 24%, 4/17 measures). This supports ongoing concerns about intensive MTX exposure as a major contributor to CNS late effects.
B
-precursor acute lymphoblastic leukemia (ALL) is the most common childhood malignancy in industrialized countries, with approximately 3 to 4 children/100,000 diagnosed annually. 1 Combination chemotherapy and aggressive central nervous system (CNS) prophylaxis have resulted in cure rates approaching 90% for patients with standard-risk ALL. 2, 3 An important component of ALL therapy is the antimetabolite methotrexate (MTX). As intravenous (IV) doses of MTX have increased over the past 2 decades, concerns about acute and chronic effects of MTX therapies have grown, particularly those affecting the CNS and cognitive function. [4] [5] [6] As early as 1978, changes on computed tomography scans of children with ALL were attributed to MTX leukoencephalopathy. 7 Subsequent studies suggested that MTX alone, in the absence of CNS leukemia or cranial irradiation, was not a major risk factor for leukoencephalopathy, although cognitive impairment was reported as children completed therapy. 8, 9 As treatment intensity with MTX increased on POG study 9005, reports of seizures, dementia, and changes on neuroimaging also increased. Two arms of the study included IV MTX 1 g/m 2 , whereas 1 used oral MTX (0.3 g/m 2 ). Acute neurotoxicity was significantly greater on the 2 study arms with IV MTX (8.3% and 11.2%) compared with the arm that used oral MTX (3.7%). Leukoencephalopathy was identified on either computed tomography or magnetic resonance imaging (MRI) in 75% and 77.1% of symptomatic patients treated on the IV MTX arms, respectively, compared with 15% of patients in the oral MTX arm. Intensification using 12 courses of repeated IV MTX in the setting of low-dose leucovorin rescue was identified as the likely risk factor. 10 Before the availability of the P9005 results, P9405, the next POG study for standard-risk ALL, utilized 12 courses of IV MTX in a regimen similar to 9005, but was closed because of unacceptable acute neurotoxicity. The next study, P9605, reduced the number of IV MTX courses from 12 to 6. This regimen was considered to be less neurotoxic as it paralleled the IV MTX courses given on the lesser-risk study P9201. In contrast to P9005, children treated on P9201, a treatment regimen for standard-risk children with favorable cytogenetics, had little evidence of acute neurotoxicity (3%). 11 In 2002, in response to concerns raised by investigators at the Roswell Park Cancer Institute, a study (ACCL0131) was mounted to compare neuroradiologic evidence of leukoencephalopathy and neurocognitive deficits in children treated on P9605 and P9201. Although (a) induction on P9605 and P9201 was the same, (b) both used the same doses and timing of IV MTX and leucovorin during consolidation, and (c) no child received radiation therapy, there were 3 differences in the treatment regimens. The first difference related to the use of triple intrathecal therapy (TIT) versus intrathecal MTX (ITM). Patients on P9605 received TIT for induction, consolidation, and maintenance until an amendment in July 1999 when TIT was replaced with ITM (because of an excessive incidence of seizures). Patients on P9201 also received TIT during induction, consolidation, and maintenance until an amendment in August 1996 when postinduction TIT was switched to ITM. In July 1999, TIT was replaced with ITM during induction for patients on P9201 as well. The second difference is highlighted in Table 1 . Patients on P9605 had 5 lumbar punctures with TIT (or ITM) delivered a week before IV MTX, (hence without leucovorin rescue), whereas those on P9201 had TIT (or ITM) concurrent with IV MTX and were consequently protected by leucovorin rescue. This created a major difference in CNS exposure to MTX. In addition, patients on P9605 received MTX 2 of every 3 weeks (either intravenously or intrathecally) on P9605, whereas patients on P9201 received no MTX for 2 weeks between doses. Finally, whereas patients on both P9201 and P9605 received induction, consolidation, and maintenance chemotherapy, patients on P9605 also received postconsolidation intensive therapy. Children on regimen 1 of the study received standard 6 mercaptopurine (6MP) (75 mg/m 2 dh) + standard MTX (20 mg/m 2 intramuscularly) weekly; those on regimen 2 received standard 6MP + divided dose MTX (25 mg/m 2 PO q6 h Â 4 every other week); those on regimen 3 received standard MTX with divided dose 6MP (37.5 mg/m 2 PO bid qd); and those on regimen 4 received divided dose MTX and divided dose 6MP. These protocols offer the unique opportunity to document whether the treatment differences impacted long-term radiologic, clinical, and cognitive neurotoxicity.
MATERIALS AND METHODS
To be eligible for ACCL0131, patients had to have "good prognosis" by NCI risk, 1.00 to 9.99 years old at diagnosis, and without evidence of CNS3 at diagnosis. Patients had to be registered after the opening of P9605 (ie, after April 1, 1996 but before amendment #8 dated July 29, 1999 or registered on P9201 after amendment #6 dated August 26, 1996) . Patient assignment to P9201 was based on cytogenetic findings in the diagnostic bone marrow, that is, the presence of trisomy 4 and 10. ACCL0131 was later amended to exclude patients who had relapsed and those with Down syndrome and to include data and materials obtained a minimum of 3 years after completion of therapy.
The study was initially limited to selected POG institutions and patients who indicated before study initiation that the imaging and neuropsychological studies could be performed. From these, a randomly selected list of potentially eligible patients was identified by the statistics center; the selected centers/patients were invited to participate in the study. Patients from Roswell Park Cancer Institute were not initially invited to participate as this site had been the first to recognize that their patients on P9605 and P9201 differed in terms of neuroimaging and neuropsychological outcomes. Later, through an amendment, the study was opened to COG group-wide and to all eligible patients. When the study was opened group-wide, the Roswell patients were included.
Local IRB approval and informed consent were obtained from all patients. Mandated studies included MRI scans of the brain and a series of standardized neuropsychological tests with population norms (Appendix).
MRI
The MRI scans consisted of axial T1, T2, and fluidattenuated inversion recovery (FLAIR) images of the entire brain. Coronal scans were not included because of cost considerations. No contrast was administered. Sedation was used on the basis of the age of the patient and anticipated level of cooperation. All MRI scans were reviewed centrally and concurrently by a neuroradiologist (K.J.H.) with experience in grading leukoencephalopathy, and a pediatric neurologist. 12 Both reviewers were blinded to the patients' treatment protocol. Although there was discussion about each case, there was no discordance. Scans were coded as normal/abnormal. Abnormal included the presence of white matter changes compatible with leukoencephalopathy. Leukoencephalopathy was defined as abnormal T2-weighted hyperintensities in the deep white matter (centrum semiovale, periventricular white matter). Leukoencephalopathy was further coded by grade, as modified by Chu et al 13 as mild (mild diffuse T2 hyperintensities in the periventricular white matter/centrum semiovale), moderate (moderate T2 hyperintensities, which extend almost to the gray-white junction), or severe (severe T2 hyperintensities involving confluent deep white matter from the frontal horns to the trigone, which may extend to the subcortical U fibers). Location was defined as anterior, posterior, or both. In addition, the presence or absence of hydrocephalus, calcification, and focal lesions were noted.
Neurocognitive Testing
Neurocognitive tests were administered by a licensed psychologist or a trained intern, fellow, or psychometrician under the direct supervision of a licensed psychologist. The specific measures, area of function assessed, and test characteristics are included in the appendix.
Study Design and Statistical Analyses
The primary aim was to compare the prevalence of neurocognitive abnormalities in children treated on P9605 versus P9201. The primary endpoint was the percentage of patients with intellectual deficit (either Verbal [VIQ] or Performance IQ [PIQ] below 85), with planning parameters of 20% VIQ or PIQ deficit for P9201 and 40% for P9605. The original design yielded 80% power with a 1-sided a level of 0.05, with accrual in 2 stages: stage 1: 30 and 60 patients from P9201 and P9605, respectively; stage 2: 24 and 48 patients from P9201 and P9605, respectively.
The study was terminated because of poor accrual before meeting the targets for stage 1. With the final number of patients for primary analysis of 16 and 31, respectively, for P9201 and P9605, the power for detecting a 20% versus 40% intelligence deficit would have been 39%. The original design used a 1-sided statistical test as the difference in only 1 direction (superiority of P9201) was of interest; there was no interest in establishing the inferiority of P9201 and no interest in differentiating between P9201 being comparable to P9605 and P9201 being worse than P9605.
Owing to lack of accrual, all analyses performed were exploratory in nature. No multiple comparison adjustments were made in any analysis. All P values were based on 2-sided tests, except the analysis comparing the frequency of intellectual deficit between P9201 and P9605, which was based on a 1-sided test per original design as indicated.
Two-sample t tests were used to compare the mean of continuous variables (such as age at diagnosis or neurocognitive test score). Comparisons of categorical variables (such as sex or presence/absence of leukoencephalopathy) between 2 groups were based on the Fisher exact test except that the w 2 test was used for comparison of race groups. Twosided exact 95% confidence interval (CI) was computed for binomial proportions. The exact test of binomial proportions was used to compare the observed percentage of patients who scored >1 SD worse than the normative mean to the expected percentage in the general population, which is 16%. Patients (N = 66) were enrolled from 16 institutions; 28 were enrolled on P9201 and 38 on P9605 between 1996 and 1999. One patient, treated on P9201, relapsed before enrollment on ACCL0131 and was excluded in all the analyses. A second patient with relapse was included in the analysis because the neuropsychological testing and MRI scan were performed before relapse. Four of 28 patients on P9201 received TIT rather than ITM because of statistical office/institutional error. Twenty-one of 38 patients on P9605 received both TIT and ITM, the amount of each depending on when they entered the treatment protocol. Six enrolled patients had neither MRI nor neuropsychological testing data available for review by the time the study was closed and are not included in any of the analyses. Thus there were 59 evaluable patients (24 from P9201 and 35 from P9605) ( Table 2) .
RESULTS

Participants
Under the original plan, 110 patients were selected from 15 POG institutions for stage 1 (target n = 90). Three of the sites never received IRB approval, eliminating 16 patients from the "invited" group. The study was later opened groupwide because of poor enrollment. Altogether 43 enrolled patients were initially invited; of those, 7 were nonevaluable due to relapse or no MRI/neuropsychological testing, leaving 36 evaluable patients. Another 23 enrolled and evaluable patients were not "invited" and were convenience samples.
MRI Results
Fifty-four patients had MRI scans performed: 23 from P9201 and 31 from P9605. There was a significant difference in the presence of leukoencephalopathy: P9201 with 5/23 (22%; 95% CI, 5%-44%) versus P9605 with 21/31 (68%; 95% CI, 49%-83%) (P = 0.001). With 1 exception, all leukoencephalopathy positive scans, on both the T2 and FLAIR sequences, were considered mild. One patient with moderate leukoencephalopathy on both the T2 and FLAIR sequences was treated on P9605. There were no cases of hydrocephalus identified. Calcification, which was considered indeterminate, was identified in 1 patient who had been treated on P9605. Focal abnormalities were identified on T1, T2, and FLAIR sequences. More focal lesions occurred on P9605 (11/31) versus P9201 (2/23) (P = 0.03) on T2 and FLAIR sequences for which the result (lesion yes/no) was the same for all patients.
Neurocognitive Outcomes
Neurocognitive evaluations were completed for 52 patients. Not all patients completed all the subtests, thus the actual number of patients for different subtests varied. Scores >1 SD from the normative mean (< 85 for standard and index scores, <7 for scaled scores, >60 for T-scores) were considered clinically meaningful, as these represented below average to impaired performance. In the general population, 16% of children would be expected to score in this range.
For the primary study endpoint, there was no significant difference in the number of patients scoring <85 on the age-appropriate Wechsler VIQ or PIQ (5/16 on P9201 [31%] vs. 14/31 on P9605 [45%], 1-sided P = 0.27). Owing to lack of accrual, the power to detect a statistically significant difference is compromised. A strong trend toward a significant mean Full Scale IQ (FSIQ) difference (P9605 [mean = 90.1] vs. P9201 [mean = 100.4]; P = 0.06) was observed. Of concern, 40% (19/47) of patients in this study had either VIQ or PIQ scores below the normative range.
In exploratory analyses, no significant differences were identified between male and female individuals in the The 2 study cohorts were compared on their performance on specific measures of function. In these exploratory analyses, significant differences were found for the Wechsler Perceptual Organization Index (P = 0.03), the Woodcock-Johnson Revised Processing Speed Cluster (P = 0.05), and the Beery Test of Visuomotor Integration (P = 0.03) with patients on P9605 having lower mean scores than those on P9201. An exception to this pattern was found for the Commission Errors of the Connors Continuous Performance Tasks (CPT), in which patients treated on P9201 performed more poorly than those treated on P9605 (Table 3) .
In a separate exploratory analysis, the percent of patients in each study who scored >1 SD worse than the normative mean were compared with the expected 16% of the normal population on the VIQ, PIQ, and FSIQ as well as on 14 subtests (excluding the Connors CPT). More than 16% of patients treated on P9605 scored >1 SD worse than the normative mean on 14/17 (82%) specific measures of neurocognitive function compared with 4/17 (24%) specific measures for patients treated on P9201 (Table 4) .
High T-scores (> 60) are indicative of clinically significant attention problems on the Connors CPT. In both studies >16% of patients scored >1 SD worse than the normative mean on the majority of CPT subtests (11/12 subtests on P9201 and 10/12 on P9605) ( Table 4) .
Comparison of MRI Leukoencephalopathy and IQ Results
Both leukoencephalopathy results and IQ data were available for 43 participants. In exploratory analyses, there was no significant difference (P = 0.36) in VIQ or PIQ < 85 based on the presence of leukoencephalopathy (11/22 with leukoencephalopathy; 7/21 without.) There were also no statistically significant differences for mean FSIQ, VIQ, or PIQ based on the presence of leukoencephalopathy.
There were significant differences on means of specific measures of attention (commissions [P = 0.05], 45.0 vs. 51.5, and omissions [P = 0.04], 48.7 vs. 67.2) based on the presence of leukoencephalopathy, with patients having leukoencephalopathy performing significantly worse on these subtests.
Among patients with neurocognitive scores >1 SD worse than the normative mean on a particular measure, the percentage with leukoencephalopathy was 80% for VIQ (8/10), 64% for PIQ (9/14), and 89% for FSIQ (8/9). For P9605, the percent with leukoencephalopathy among those scoring worse than the normative mean was 87.5% (7/8) for VIQ, 81.8% (9/11) for PIQ, and 100% (8/8) for FSIQ. For tests measuring verbal comprehension, perceptual organization, processing speed, freedom from distractibility, memory, and visuo-motor integration, between 75% and 100% of patients treated on P9605 with abnormal performance (> 1 SD worse than the normative mean) also had leukoencephalopathy.
DISCUSSION
The goal of this study was to determine whether there were differences in neurocognitive function and neuroradiologic findings of leukoencephalopathy in children treated on P9605 and P9201.
We report a number of important findings. First, significantly more patients treated on P9605 had leukoencephalopathy than did those treated on P9201. Whereas some authors have questioned the significance of transient white matter changes, white matter changes in this study were not transient, with some identified as late as 7.7 years after completion of treatment. 14 A report of a small, single-institution study of children undergoing active treatment on P9605 found that 78% of patients had white matter changes on at least 1 MRI. 15 When their short-term results are viewed in the context of the long-term outcomes of patients on P9605, persistent white matter changes are evident in the majority.
Second, although there were no statistically significant differences between the studies in the number of children with VIQ or PIQ < 85 (> 1 SD worse than the normative mean of the general population), 40% of the total group of patients treated on P9605 and P9201 had PIQ or VIQ scores that were abnormal compared with the general population. Neurocognitive late effects related to ALL treatment have been repeatedly identified in the specific areas of attention, freedom from distractibility, speed of information processing, verbal memory, visual memory, verbal comprehension, visuospatial skills, visuo-motor integration, and executive function. [16] [17] [18] [19] [20] [21] [22] We found similar areas of neurocognitive weakness with the exception of verbal memory and executive function.
Third, there was a strong relationship between MRI evidence of leukoencephalopathy and neurocognitive function. Although there were no differences between those with/without leukoencephalopathy on measures of global cognitive function (FSIQ, VIQ, PIQ), the majority (75% to 100%) of children treated on P9605 who scored >1 SD worse than the normative mean on areas of specific neurocognitive function also had leukoencephalopathy. The difficulty with interpreting these data is that most of the patients treated on P9605, with and without abnormal cognitive testing, had leukoencephalopathy. Whether larger numbers of patients in this cohort would have yielded statistically significant results is unknown. In addition, conventional MRI >5 years from diagnosis may not adequately reflect lasting neurocognitive effects of acute white matter injury nor does it quantify changes due to myelin or axonal injury. Other imaging approaches such as white matter anisotropy or diffusion and structural/functional white matter connectivity should be considered to advance understanding in subsequent studies. 16 In summary, patients treated on P9605 fared significantly worse in terms of leukoencephalopathy than patients treated on P9201. In addition, patients on P9605 performed worse than the general population (> 16% scored >1 SD worse than the normative mean) on more tests of neuropsychological function than those treated on P9201, with the exception of the Connors CPT in which both groups performed worse than the general population. This suggests that differences in protocol design of P9201 reduced the incidence of both leukoencephalopathy and neurocognitive damage compared with P9605. There were 3 important differences in the treatment regimens of the 2 protocols. The first involved the administration of TIT versus ITM during consolidation and maintenance. Although both protocols were amended in 1999 to replace TIT with ITM, before that patients on P9605 received TIT throughout the treatment, whereas patients from P9201 who were eligible for ACCL0131 (ie, after amendment in August 1996) received TIT only during induction. This issue is complex, however, as some patients were entered on treatment before the 1999 amendment and continued treatment afterward, thus receiving both TIT and ITM during their course of treatment. It is unlikely, however, that the difference in IT medications influenced long-term neurototoxicity as Kadan-Lottick et al 23 found no significant differences in neuropsychological function between children treated with TIT versus those treated with ITM.
It is likely that the differences in intensive CNS therapy during consolidation were a more important contributing factor, that is, the administration of leucovorin after all IT courses for patients on P9201 (hence reducing CNS exposure) and the difference in the timing of MTX administration. Patients on P9605 received MTX, either IV or IT, 2 of every 3 weeks, whereas patients on P9201 had 2 weeks between courses. It is possible that the frequent administration of "unprotected" ITM in P9605 may have depleted folic acid stores in the CNS and not allowed the brain to recover sufficiently before the next dose was given.
The significance of the third difference between the treatment regimes, that is, the postconsolidation intensive therapy on P9605, is more difficult to interpret because of the multiplicity of regimens and the limited number of patients. The possible role of divided dose MTX and/or 6MP in 3 of the 4 arms needs clarification in future studies.
Finally, an area of particular weakness for patients treated on both studies was in attention and distractibility, deficits that are likely to have an impact on future educational success. The fact that these impairments were found in both groups suggests that there may be a subgroup of children with genetic risk factors (eg, polymorphisms related to folate metabolism) that make them particularly vulnerable to the adverse effects of MTX. 24 As CSF folate levels were not requested, this is only speculative.
Although the results of this study are concerning, conclusions are limited by the relatively small number of patients. Unfortunately, this is a frequent limitation of lateeffects studies even when the cost of neuropsychological studies is covered. 25 In addition, it is possible that selection bias may have been a factor in the results. It is not clear why some families refused to enter their children in the study while others agreed to do so. It is possible, although by no means certain, that those who had children with academic issues may have been more interested in pursuing the neuropsychological testing.
In 2002, an editorial was written in the Journal of Pediatric Hematology/Oncology entitled "More good news about neuropsychological late effects in long-term survivors of acute lymphoblastic leukemia." 26 Although it is true that children with ALL treated with cranial irradiation for CNS prophylaxis during the 1980s had far greater neuropsychological deficits, our results suggest that the chemotherapy protocols of the late 1990s were far from benign. Current COG protocols do not give intensive/frequent IT MTX interspaced with high-dose IV MTX, a practice our data would support.
